Stock Track | Senseonics Soars Over 8% Pre-Market on Eversense 365 Integration with SweetSpot for Enhanced Diabetes Care

Stock Track

26 Feb

Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.

The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.

Dr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it "removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care." The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1195757632"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195757632\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1195757632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195757632","market":"us","top_or_hot":-1,"title":"Stock Track | Senseonics Soars Over 8% Pre-Market on Eversense 365 Integration with SweetSpot for Enhanced Diabetes Care","media":"Stock Track","content":"<html><body><p>Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.</p>\n<p>The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.</p>\n<p>Dr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it \"removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care.\" The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Senseonics Soars Over 8% Pre-Market on Eversense 365 Integration with SweetSpot for Enhanced Diabetes Care</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Senseonics Soars Over 8% Pre-Market on Eversense 365 Integration with SweetSpot for Enhanced Diabetes Care\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 22:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.</p>\n<p>The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.</p>\n<p>Dr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it \"removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care.\" The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SENS","symbol_name":"Senseonics Holdings,Inc.","start_time":0,"source_url":"","article_id":"1195757632","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195757632","pubTimestamp":1740581671,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Senseonics Holdings, Inc. , the developer of the Eversense 365 Continuous Glucose Monitoring  System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patien","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SENS":"Senseonics Holdings,Inc."},"translate_title":"股票跟踪Senseonics因Eversense 365与SweetSpot集成以增强糖尿病护理而盘前飙升超过8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SENS":1},"content_text":"Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring over 8% in pre-market trading on Wednesday.\nThe pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system. The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.\nDr. Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, expressed excitement about the integration, stating that it \"removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care.\" The integration aligns with SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for partners.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}